News

Holly Chitwood, DNP, APRN, FNP-C, AGACNP-BC, shares her real-world experience with circulating-tumor-DNA monitoring in the colorectal cancer setting.

Data from a single-institution study showed that 98.6% of their patients with head and neck cancer experienced oral mucositis.

Those receiving dostarlimab experienced numerical improvements from baseline in terms of quality of life, emotional functioning, pain, and back and pelvis pain scores.

Melanie Taylor, APRN, and Mark Lin, APRN, share how they optimize strategies in caring for patients with lymphedema.

Proper counseling is needed to help decrease fertility-related psychological distress in adolescent/young adult cancer survivors.

Advanced practice providers were more likely to be impacted by prior authorizations than their physician colleagues, according to survey responses.

Steroids are the standard approach in immune-related adverse events; however, some experts maintain that other management strategies are needed.

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

The FDA has expanded the indication for enzalutamide to include patients with high-risk nonmetastatic castration-sensitive prostate cancer.

Tammy Triglianos, DNP, ANP-BC, AOCNP, discusses optimal adjuvant treatment approaches for patients with stage III colon cancer.

The FDA has approved capivasertib plus fulvestrant to treat patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.

The FDA has approved pembrolizumab plus chemotherapy to treat adults with locally advanced or metastatic, HER2-negative gastric cancers.

Following the pandemic, rates of violence in health care are still high.

Repotrectinib is now available to treat adults with advanced or metastatic non-small cell lung cancer that harbors a ROS1 fusion.

The PD-L1 IHC 22C3 pharmDx diagnostic tool will help identify patients with gastric or gastroesophageal junction adenocarcinoma whose disease expresses PD-L1 and who are thereby eligible for pembrolizumab.

Like patients, caregivers need education and support, but are often forgotten or unheard.

Leveraging circulating tumor (ct)DNA may help expedite the time to treatment and enhance survival prospects for individuals with lung cancer.

A phase 3 trial based out of India suggests that olanzapine may be useful in reducing chemotherapy-induced nausea and vomiting.

The FDA has restricted the indication for gastric cancer to only include patients whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test.

New ASCO guidelines recommend trilaciclib for patients with untreated or previously treated extensive-stage small cell lung cancer who are receiving chemotherapy or chemoimmunotherapy.

Lisocabtagene maraleucel is under consideration as a potential treatment option for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Patients who were in the intervention arm were 67% less likely to go to the emergency department in the last days of their life.

The median OS achieved with atezolizumab plus bevacizumab and chemotherapy was 32.1 months vs 22.8 months with bevacizumab and chemotherapy alone.

The Undiagnosed Cancer Clinic, or UCC, was established with the goal of reducing the time that patients wait for their initial oncology consultation appointments.

The FDA has approved fruquintinib to treat adults with metastatic colorectal cancer.

Screening for financial toxicity should be routine in cancer care, according to investigators.

Incorporating frailty screenings into preexisting workflows may be an effective way to provide more holistic care to patients with head and neck cancer.

Investigators reflect on the Oncology Care Model and its implications.

The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.

The duration of response was 39.2 months among patients with 1 metastatic site treated in the combination arm vs 29.5 months for patients given sunitinib.